120 related articles for article (PubMed ID: 9194148)
21. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex.
Kuroki T; Ichikawa J; Dai J; Meltzer HY
Brain Res; 1996 Dec; 743(1-2):357-61. PubMed ID: 9017269
[TBL] [Abstract][Full Text] [Related]
22. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux.
Prus AJ; Huang M; Li Z; Dai J; Meltzer HY
Brain Res; 2007 Dec; 1184():354-64. PubMed ID: 17988654
[TBL] [Abstract][Full Text] [Related]
23. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex.
Pehek EA; McFarlane HG; Maguschak K; Price B; Pluto CP
Brain Res; 2001 Jan; 888(1):51-59. PubMed ID: 11146051
[TBL] [Abstract][Full Text] [Related]
24. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Ichikawa J; Chung YC; Li Z; Dai J; Meltzer HY
Brain Res; 2002 Dec; 958(1):176-84. PubMed ID: 12468043
[TBL] [Abstract][Full Text] [Related]
25. Systemic and intra-accumbens administration of amphetamine differentially affects cortical acetylcholine release.
Arnold HM; Nelson CL; Neigh GN; Sarter M; Bruno JP
Neuroscience; 2000; 96(4):675-85. PubMed ID: 10727786
[TBL] [Abstract][Full Text] [Related]
26. Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion.
Ventura R; Alcaro A; Cabib S; Conversi D; Mandolesi L; Puglisi-Allegra S
Neuropsychopharmacology; 2004 Jan; 29(1):72-80. PubMed ID: 12968132
[TBL] [Abstract][Full Text] [Related]
27. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
28. 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity.
Charron A; Hage CE; Servonnet A; Samaha AN
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2381-93. PubMed ID: 26508706
[TBL] [Abstract][Full Text] [Related]
29. Behavioral and biochemical effects of amperozide and serotonin agents on nigrostriatal and mesolimbic dopamine systems.
Chang PY; Chuang CH; Chen JC; Tung CS
Chin J Physiol; 2008 Apr; 51(2):106-15. PubMed ID: 18666714
[TBL] [Abstract][Full Text] [Related]
30. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function.
Sershen H; Balla A; Aspromonte JM; Xie S; Cooper TB; Javitt DC
Neurochem Int; 2008 Jan; 52(1-2):119-29. PubMed ID: 17716783
[TBL] [Abstract][Full Text] [Related]
31. 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices.
Ramírez MJ; Cenarruzabeitia E; Lasheras B; Del Rio J
Brain Res; 1997 May; 757(1):17-23. PubMed ID: 9200494
[TBL] [Abstract][Full Text] [Related]
32. Amphetamine-stimulated cortical acetylcholine release: role of the basal forebrain.
Arnold HM; Fadel J; Sarter M; Bruno JP
Brain Res; 2001 Mar; 894(1):74-87. PubMed ID: 11245817
[TBL] [Abstract][Full Text] [Related]
33. Modulation of dopamine release by striatal 5-HT2C receptors.
Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
[TBL] [Abstract][Full Text] [Related]
34. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release.
Broderick PA; Piercey MF
J Neural Transm (Vienna); 1998; 105(6-7):749-67. PubMed ID: 9826116
[TBL] [Abstract][Full Text] [Related]
35. In-vivo effects of the 1,2,4-piperazine derivatives MM5 and MC1, putative 5-HT agonists, on dopamine and serotonin release in rat prefrontal cortex.
Iskra-Jopa J; Gołembiowska K; Dziubina A; Cybulski M; Duszyńska B; Chilmonczyk Z
J Pharm Pharmacol; 2005 Feb; 57(2):205-11. PubMed ID: 15720784
[TBL] [Abstract][Full Text] [Related]
36. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.
Lucas G; Bonhomme N; De Deurwaerdère P; Le Moal M; Spampinato U
Psychopharmacology (Berl); 1997 May; 131(1):57-63. PubMed ID: 9181636
[TBL] [Abstract][Full Text] [Related]
37. DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum.
Ichikawa J; Meltzer HY
Brain Res; 1995 Nov; 698(1-2):204-8. PubMed ID: 8581482
[TBL] [Abstract][Full Text] [Related]
38. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat.
Hertel P; Mathé JM; Nomikos GG; Iurlo M; Mathé AA; Svensson TH
Behav Brain Res; 1995 Dec; 72(1-2):103-14. PubMed ID: 8788863
[TBL] [Abstract][Full Text] [Related]
39. 17β-Estradiol infusions into the dorsal striatum rapidly increase dorsal striatal dopamine release in vivo.
Shams WM; Sanio C; Quinlan MG; Brake WG
Neuroscience; 2016 Aug; 330():162-70. PubMed ID: 27256507
[TBL] [Abstract][Full Text] [Related]
40. Regulation of medial prefrontal cortex dopamine by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptors.
Wu WR; Li N; Sorg BA
Neuroscience; 2002; 114(2):507-16. PubMed ID: 12204218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
